Point72 Asset Management
HRTX icon

Point72 Asset Management’s Heron Therapeutics HRTX Stock Holding History

Point72 Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,775,877
Closed -$10.5M – 2379
2025
Q1 		$10.5M Buy
4,775,877
+1,700,068
+55% +$3.3M 0.02% 665
2024
Q4 		$4.71M Buy
+3,075,809
New +$4.99M 0.01% 970
2024
Q2 		– Sell
-5,600
Closed -$15.5K – 2109
2024
Q1 		$15.5K Buy
+5,600
New +$14.1K ﹤0.01% 2102
2023
Q3 		– Sell
-22
Closed -$26 – 2640
2023
Q2 		$26 Sell
22
-34,012
-100% -$60.7K ﹤0.01% 2088
2023
Q1 		$51.4K Buy
+34,034
New +$85.2K ﹤0.01% 1777
2021
Q4 		– Sell
-1,600,486
Closed -$17.1M – 1185
2021
Q3 		$17.1M Buy
1,600,486
+1,357,037
+557% +$16.5M 0.08% 350
2021
Q2 		$3.78M Buy
243,449
+178,449
+275% +$2.84M 0.02% 656
2021
Q1 		$1.05M Sell
65,000
-45,382
-41% -$809K ﹤0.01% 796
2020
Q4 		$2.34M Sell
110,382
-150,959
-58% -$2.62M 0.01% 709
2020
Q3 		$3.87M Buy
+261,341
New +$4.08M 0.02% 615
2019
Q2 		– Sell
-173,700
Closed -$4.25M – 1418
2019
Q1 		$4.25M Buy
+173,700
New +$4.55M 0.02% 590
2018
Q3 		– Sell
-20,000
Closed -$777K – 1093
2018
Q2 		$777K Buy
+20,000
New +$637K ﹤0.01% 852
2017
Q2 		– Sell
-133,483
Closed -$2M – 903
2017
Q1 		$2M Buy
+133,483
New +$1.85M 0.01% 670
2015
Q4 		– Sell
-1,100
Closed -$27K – 743
2015
Q3 		$27K Sell
1,100
-250,400
-100% -$8.34M ﹤0.01% 725
2015
Q2 		$7.84M Sell
251,500
-248,500
-50% -$4.68M 0.05% 373
2015
Q1 		$7.28M Sell
500,000
-10,100
-2% -$114K 0.05% 389
2014
Q4 		$5.13M Buy
+510,100
New +$4.16M 0.04% 430

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management's HRTX Position: Q2 2025 in Review

Point72 Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 4,775,877 shares — an estimated $10.5M sold.

Point72 Asset Management first reported a position in HRTX in Q4 2014 and held it in 17 quarters. The position peaked at $17.1M in Q3 2021. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Point72 Asset Management reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 4,775,877 Heron Therapeutics shares in Q2 2025, an estimated $10.5M.
  • Point72 Asset Management first reported a position in Heron Therapeutics in Q4 2014 and held it in 17 quarters.
  • Point72 Asset Management's Heron Therapeutics position peaked at $17.1M in Q3 2021.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.